Key Highlights
- Shares of AbCellera surged 32% to reach $9.12 following positive Phase 2 data for menopause treatment ABCL635
- The experimental therapy demonstrated a reduction of 8.8 hot flash episodes daily compared to just 3.5 in the placebo arm
- Trial participants experienced improved symptom severity scores and better sleep quality outcomes
- The randomized, double-blind, placebo-controlled study included 92 postmenopausal participants
- The four-week treatment period saw zero serious adverse events among participants
Shares of AbCellera (ABCL) experienced a dramatic 32% rally to $9.12 during Monday’s trading session following the announcement of encouraging Phase 2 clinical trial data for its investigational menopause therapy.
AbCellera Biologics Inc., ABCL
Prior to Monday’s announcement, the stock had already experienced substantial gains in 2026, with much of that momentum building on investor expectations surrounding this critical data release.
The investigational drug ABCL635 represents a non-hormonal alternative delivered via a single subcutaneous injection designed for extended duration action. The therapeutic agent works by targeting the neurokinin 3 receptor, a biological pathway implicated in the physiological mechanism of hot flash generation.
The Phase 2 clinical investigation recruited 92 women in the postmenopausal phase who reported experiencing approximately 10 moderate-to-severe hot flash episodes daily. Study participants were randomly assigned to receive either a single 600mg subcutaneous administration of ABCL635 or an inactive placebo injection.
At the four-week assessment point, the study successfully achieved its primary efficacy objectives. This indicates that the therapeutic candidate reached the predetermined statistical benchmarks established by the company to declare the trial successful.
Clinical Outcomes Breakdown
Regarding hot flash frequency metrics, participants receiving ABCL635 experienced a decrease of 8.8 moderate-to-severe episodes daily from their initial baseline measurements. Meanwhile, those in the placebo arm showed only a 3.5-event reduction. This translates to a placebo-adjusted treatment benefit of 5.3 fewer hot flash episodes per day.
When examining severity measurements, the active treatment group demonstrated a 1.4-point reduction in severity scores at the four-week mark, while placebo recipients saw merely a 0.3-point improvement. The placebo-adjusted benefit stood at 1.1 points.
Beyond the primary endpoints, individuals treated with ABCL635 documented enhanced sleep quality and expressed overall improvement in their wellbeing, as measured through the patient global impression of change assessment tool.
The clinical investigation followed a randomized, double-blind, placebo-controlled methodology, representing the gold-standard approach for this category of therapeutic evaluation.
Tolerability and Safety Data
Throughout the four-week study duration, the investigational treatment demonstrated favorable tolerability characteristics. Researchers reported zero serious adverse events, zero severe adverse events, and no study discontinuations attributable to treatment-related side effects.
The adverse events occurring most frequently among ABCL635 recipients included headache, fatigue, and reactions at the injection site.
AbCellera convened a conference call on Monday to provide detailed discussion of the trial outcomes with the investment community and financial analysts.
The biotechnology company is strategically positioning ABCL635 as a non-hormonal therapeutic alternative, potentially addressing the needs of patients who are unable to utilize or prefer to avoid hormone replacement therapies.
ABCL shares finished Monday’s trading session at $9.12, representing a 32% gain for the day.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
